Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
8
CLRB Quote, Financials, Valuation and Earnings
Last price:
$2.54
Seasonality move
:
-3.89%
Day range:
$2.44 - $2.63
52-week range:
$2.43 - $20.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
137.94x
P/B ratio:
1.37x
Volume:
30.7K
Avg. volume:
47.8K
1-year change:
-71.86%
Market cap:
$11M
Revenue:
--
EPS (TTM):
-$6.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CLRB
Cellectar Biosciences, Inc.
|
-- | -$1.89 | -- | -1215.42% | $33.33 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$283.1M | $0.07 | 16.03% | -30.17% | $31.85 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.1B | $1.53 | 88.89% | -58.59% | $449.32 |
|
EYPT
EyePoint Plc
|
$352.8K | -$0.81 | -98.65% | -25.43% | $37.42 |
|
OCGN
Ocugen, Inc.
|
$358.1K | -$0.05 | -75.82% | -1.77% | $11.57 |
|
SVRA
Savara, Inc.
|
-- | -$0.14 | -- | -12.28% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CLRB
Cellectar Biosciences, Inc.
|
$2.55 | $33.33 | $11M | -- | $0.00 | 0% | 137.94x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.20 | $31.85 | $3.8B | 9.65x | $0.00 | 0% | 3.49x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$318.85 | $449.32 | $41B | 141.27x | $0.00 | 0% | 11.46x |
|
EYPT
EyePoint Plc
|
$13.40 | $37.42 | $1.1B | -- | $0.00 | 0% | 31.28x |
|
OCGN
Ocugen, Inc.
|
$1.79 | $11.57 | $585.3M | -- | $0.00 | 0% | 121.39x |
|
SVRA
Savara, Inc.
|
$5.56 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CLRB
Cellectar Biosciences, Inc.
|
3.97% | 1.526 | 2.84% | 2.78x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.662 | 5.64% | 2.51x |
|
EYPT
EyePoint Plc
|
6.93% | 2.071 | 1.51% | 8.28x |
|
OCGN
Ocugen, Inc.
|
157.99% | 2.046 | 7.86% | 0.81x |
|
SVRA
Savara, Inc.
|
12.84% | -1.345 | 2.43% | 11.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CLRB
Cellectar Biosciences, Inc.
|
-$49.5K | -$5.7M | -200.5% | -209.22% | -- | -$4.4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
EYPT
EyePoint Plc
|
-$104K | -$70.3M | -77.2% | -83.61% | -11345.97% | -$66M |
|
OCGN
Ocugen, Inc.
|
-- | -$17M | -166.93% | -848.82% | 8805.7% | -$14M |
|
SVRA
Savara, Inc.
|
-$40K | -$33.4M | -67.27% | -80.59% | -- | -$25.1M |
Cellectar Biosciences, Inc. vs. Competitors
-
Which has Higher Returns CLRB or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of 96.33%. Cellectar Biosciences, Inc.'s return on equity of -209.22% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.25 $10.3M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About CLRB or ACAD?
Cellectar Biosciences, Inc. has a consensus price target of $33.33, signalling upside risk potential of 1207.19%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 43.47%. Given that Cellectar Biosciences, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Cellectar Biosciences, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 0 0 ACADACADIA Pharmaceuticals, Inc.12 4 1 -
Is CLRB or ACAD More Risky?
Cellectar Biosciences, Inc. has a beta of 0.409, which suggesting that the stock is 59.123% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.67%.
-
Which is a Better Dividend Stock CLRB or ACAD?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or ACAD?
Cellectar Biosciences, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Cellectar Biosciences, Inc.'s net income of -$5.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus 3.49x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$5.3M ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M
-
Which has Higher Returns CLRB or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of 16.99%. Cellectar Biosciences, Inc.'s return on equity of -209.22% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.25 $10.3M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About CLRB or ALNY?
Cellectar Biosciences, Inc. has a consensus price target of $33.33, signalling upside risk potential of 1207.19%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that Cellectar Biosciences, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Cellectar Biosciences, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 0 0 ALNYAlnylam Pharmaceuticals, Inc.14 8 0 -
Is CLRB or ALNY More Risky?
Cellectar Biosciences, Inc. has a beta of 0.409, which suggesting that the stock is 59.123% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.
-
Which is a Better Dividend Stock CLRB or ALNY?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or ALNY?
Cellectar Biosciences, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Cellectar Biosciences, Inc.'s net income of -$5.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus 11.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$5.3M ALNYAlnylam Pharmaceuticals, Inc.11.46x 141.27x $1.1B $186.4M
-
Which has Higher Returns CLRB or EYPT?
EyePoint Plc has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of -10904.68%. Cellectar Biosciences, Inc.'s return on equity of -209.22% beat EyePoint Plc's return on equity of -83.61%.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.25 $10.3M EYPTEyePoint Plc-16.77% -$0.81 $328.9M -
What do Analysts Say About CLRB or EYPT?
Cellectar Biosciences, Inc. has a consensus price target of $33.33, signalling upside risk potential of 1207.19%. On the other hand EyePoint Plc has an analysts' consensus of $37.42 which suggests that it could grow by 179.23%. Given that Cellectar Biosciences, Inc. has higher upside potential than EyePoint Plc, analysts believe Cellectar Biosciences, Inc. is more attractive than EyePoint Plc.
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 0 0 EYPTEyePoint Plc10 0 0 -
Is CLRB or EYPT More Risky?
Cellectar Biosciences, Inc. has a beta of 0.409, which suggesting that the stock is 59.123% less volatile than S&P 500. In comparison EyePoint Plc has a beta of 1.891, suggesting its more volatile than the S&P 500 by 89.146%.
-
Which is a Better Dividend Stock CLRB or EYPT?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. EyePoint Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or EYPT?
Cellectar Biosciences, Inc. quarterly revenues are --, which are smaller than EyePoint Plc quarterly revenues of $620K. Cellectar Biosciences, Inc.'s net income of -$5.3M is higher than EyePoint Plc's net income of -$67.6M. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while EyePoint Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus 31.28x for EyePoint Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$5.3M EYPTEyePoint Plc31.28x -- $620K -$67.6M
-
Which has Higher Returns CLRB or OCGN?
Ocugen, Inc. has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of -1144.46%. Cellectar Biosciences, Inc.'s return on equity of -209.22% beat Ocugen, Inc.'s return on equity of -848.82%.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.25 $10.3M OCGNOcugen, Inc.-- -$0.06 $21M -
What do Analysts Say About CLRB or OCGN?
Cellectar Biosciences, Inc. has a consensus price target of $33.33, signalling upside risk potential of 1207.19%. On the other hand Ocugen, Inc. has an analysts' consensus of $11.57 which suggests that it could grow by 546.45%. Given that Cellectar Biosciences, Inc. has higher upside potential than Ocugen, Inc., analysts believe Cellectar Biosciences, Inc. is more attractive than Ocugen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 0 0 OCGNOcugen, Inc.6 0 0 -
Is CLRB or OCGN More Risky?
Cellectar Biosciences, Inc. has a beta of 0.409, which suggesting that the stock is 59.123% less volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 2.803, suggesting its more volatile than the S&P 500 by 180.305%.
-
Which is a Better Dividend Stock CLRB or OCGN?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or OCGN?
Cellectar Biosciences, Inc. quarterly revenues are --, which are larger than Ocugen, Inc. quarterly revenues of -$193K. Cellectar Biosciences, Inc.'s net income of -$5.3M is higher than Ocugen, Inc.'s net income of -$17.7M. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus 121.39x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$5.3M OCGNOcugen, Inc.121.39x -- -$193K -$17.7M
-
Which has Higher Returns CLRB or SVRA?
Savara, Inc. has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of --. Cellectar Biosciences, Inc.'s return on equity of -209.22% beat Savara, Inc.'s return on equity of -80.59%.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.25 $10.3M SVRASavara, Inc.-- -$0.13 $233M -
What do Analysts Say About CLRB or SVRA?
Cellectar Biosciences, Inc. has a consensus price target of $33.33, signalling upside risk potential of 1207.19%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 94.47%. Given that Cellectar Biosciences, Inc. has higher upside potential than Savara, Inc., analysts believe Cellectar Biosciences, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 0 0 SVRASavara, Inc.6 0 0 -
Is CLRB or SVRA More Risky?
Cellectar Biosciences, Inc. has a beta of 0.409, which suggesting that the stock is 59.123% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.412%.
-
Which is a Better Dividend Stock CLRB or SVRA?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or SVRA?
Cellectar Biosciences, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Cellectar Biosciences, Inc.'s net income of -$5.3M is higher than Savara, Inc.'s net income of -$32.2M. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$5.3M SVRASavara, Inc.-- -- -- -$32.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
